ANBT
ALXN

American National Bank & Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

American National Bank & Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed – – 328
2016
Q4 		$0 Buy
+1
New +$122 ﹤0.01% 298

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

American National Bank & Trust's ALXN Position: Q1 2017 in Review

American National Bank & Trust sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 1 share.

American National Bank & Trust first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $0 in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • American National Bank & Trust reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • American National Bank & Trust sold 1 Alexion Pharmaceuticals share in Q1 2017.
  • American National Bank & Trust first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • American National Bank & Trust's Alexion Pharmaceuticals position peaked at $0 in Q4 2016.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on American National Bank & Trust's 13F filing for Q1 2017, filed 14 Apr 2017.